Valemetostat

Drug profile

Key facts

Valemetostat is a drug catalogued in DrugCentral. It was first approved by the PMDA in 2022. DrugCentral lists 2 molecular targets, including EZH2 and EZH1. Recorded indications include Relapsed or refractory T-cell leukemia-lymphoma.

• Molecular targets: EZH2 and EZH1 (2 listed in DrugCentral).
• Indications: Relapsed or refractory T-cell leukemia-lymphoma.
• Molecular formula: C26H34ClN3O4; molecular weight 488.03 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

• Relapsed or refractory T-cell leukemia-lymphoma

Mechanism & targets

Molecular targets (2)

Target	Gene	Action	Activity
Histone-lysine N-methyltransferase EZH2	EZH2	inhibitor	IC50 8.22
Histone-lysine N-methyltransferase EZH1	EZH1	inhibitor	IC50 8.00

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
2022-09-26	PMDA	—	DAIICHI SANKYO COMPANY, LIMITED	Yes

Chemical structure

• Molecular formula: C₂₆H₃₄ClN₃O₄
• Molecular weight: 488.03 g/mol
• CAS number: 1809336-39-7
• InChIKey: SSDRNUPMYCFXGM-UYPAYLBCSA-N
• PubChem CID: 126481870

CN(C)[C@H]1CC[C@@H](CC1)[C@@]1(C)OC2=C(Cl)C=C(C(=O)NCC3=C(C)C=C(C)NC3=O)C(C)=C2O1

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Valemetostat used for?

DrugCentral lists the following indications for Valemetostat: Relapsed or refractory T-cell leukemia-lymphoma.

How does Valemetostat work?

Its molecular targets in DrugCentral include EZH2 (inhibitor) and EZH1 (inhibitor).

When was Valemetostat first approved?

Valemetostat was first approved by the PMDA in 2022.

What is the chemical formula of Valemetostat?

Valemetostat has the molecular formula C26H34ClN3O4 and a molecular weight of 488.03 g/mol.

Sources

• DrugCentral drug card 5724 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL4594405 — compound record and bioactivity
• PubChem CID 126481870 — chemical identifiers
• FDA UNII 60RD0234VE — substance identity
• UniProt Q15910 (EZH2) — target protein
• UniProt Q92800 (EZH1) — target protein

How this page is built: methodology · editorial policy & corrections.